Comparative Pharmacology
Head-to-head clinical analysis: MICAFUNGIN versus REZZAYO.
Peer-Reviewed Evidence
Head-to-head clinical analysis: MICAFUNGIN versus REZZAYO.
MICAFUNGIN vs REZZAYO
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Inhibits the synthesis of 1,3-β-D-glucan, an essential component of the fungal cell wall, via inhibition of 1,3-β-D-glucan synthase.
Rezafungin is an echinocandin antifungal that inhibits the synthesis of 1,3-β-D-glucan, an essential component of the fungal cell wall, leading to osmotic instability and cell death.
100 mg intravenously once daily. For esophageal candidiasis: 150 mg intravenously once daily. Loading dose not required.
Intravenous: 2 mg/kg once daily, with a maximum of 200 mg per dose.
None Documented
None Documented
Terminal elimination half-life is approximately 10-17 hours in healthy adults. In critically ill patients, it may be prolonged (up to 20-25 hours). Half-life is dose-independent.
Clinical Note
moderateMicafungin + Tranilast
"The risk or severity of adverse effects can be increased when Micafungin is combined with Tranilast."
Clinical Note
moderateMicafungin + Tolfenamic acid
"The risk or severity of adverse effects can be increased when Micafungin is combined with Tolfenamic acid."
Clinical Note
moderateMicafungin + Nimesulide
"The risk or severity of adverse effects can be increased when Micafungin is combined with Nimesulide."
Clinical Note
moderateMicafungin + Risedronic acid
Terminal elimination half-life approximately 13.3 hours in healthy subjects; at steady state, half-life ranges from 7.3 to 13.6 hours in patients with candidemia/invasive candidiasis.
Primarily biliary/fecal (approximately 71% of administered dose recovered in feces as parent drug and metabolites), with renal excretion accounting for about 12% (mostly as metabolites, <1% unchanged). A small amount is excreted in urine.
Elimination primarily via feces (approximately 60% of dose) and urine (approximately 20% of dose) as unchanged drug and metabolites.
Category C
Category C
Antifungal (Echinocandin)
Antifungal (Echinocandin)
"The risk or severity of adverse effects can be increased when Micafungin is combined with Risedronic acid."